Swiss Noema Pharma raises CHF54m in Series A financing
Noema Pharma AG kicks off with CHF54m and licenced drug candidates from Roche AG.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
Entries by Thomas Gabrielczyk
Germany first EU country to launch COVID-19 therapy offensive?
/in News/by Thomas GabrielczykAfter months of lobbying by the BIOM biotech cluster, Bavaria is launching a 50m initiative to push the best and fastest COVID-19 therapies.
Moderna to file for EU approval of mRNA-1273 vaccine
/in News/by Thomas GabrielczykCOVID-19 mRNA vaccine developer Moderna Inc reported it will file for FDA and EMA authorisation of mRNA-1273 based on Phase III results.
Drug set to rescue COVID-19 patients at ICUs
/in News/by Thomas GabrielczykAviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients.
Polyphor AG bags funding for murepavadin
/in News/by Thomas GabrielczykPolyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.
EU COVID-19 antibody ready for clinical trials
/in News/by Thomas GabrielczykAs investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics candidate COR101 is set to enter clinical testing.
COVID-19: Moderna reports promising interim results
/in News/by Thomas GabrielczykAfter BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%.
BioNTech reports high efficacy of COVID-19 vaccine
/in News/by Thomas GabrielczykInterim data on BioNtechs/Pfizers COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA.
Vifor Pharma inks $340m deal with Angion Biomedica Inc.
/in News/by Thomas GabrielczykSwiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedicas experimental kidney drug ANG-3777.
Cell and gene therapy specialist Minaris expanding
/in News/by Thomas GabrielczykJapanese CDMO Minaris Regenerative Medicine Co. Ltd will invest US$64.5m to expand its facilities in Europe and Asia.